Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

CAR-T therapy and impact to cancer patient outcomes and experience of treatment

Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen...

CAR-T therapy and impact to cancer patient outcomes and experience of treatment ( Mr Matthias Hellberg-Naegele - Cantonal Hospital St Gallen, St Gallen, Switzerland )

Haemato-oncological Cancers

Dr Nikita Mehra - Cancer Institute (WIA), Chennai, India

Haemato-oncological Cancers ( Dr Nikita Mehra - Cancer Institute (WIA), Chennai, India )

Selpercatinib benefit, with or without pembro, in first-line advanced RET...

Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLC ( Dr Herbert Ho Fung Loong - The Chinese University of Hong Kong, Hong Kong )

ESMO 2023: Latest updates in mRCC

Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane...

ESMO 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Laurence Albiges, Prof Viktor Grünwald and Prof Stéphane Oudard )

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer

Dr Aditya Bardia - Mass General Cancer Center, Boston, USA

Datopotamab deruxtecan extends PFS vs chemo for HR+/HER2- breast cancer ( Dr Aditya Bardia - Mass General Cancer Center, Boston, USA )

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced...

Prof Thomas Powles - Barts Cancer Centre, London, UK

Enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer ( Prof Thomas Powles - Barts Cancer Centre, London, UK )

Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC

Dr Michiel Van der Heijden - Netherlands Cancer Institute, Amsterdam...

Nivolumab plus gemcitabine-cisplatin shows benefit for locally advanced mUC ( Dr Michiel Van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Durvalumab addition to chemo shows endometrial cancer benefit

Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston...

Durvalumab addition to chemo shows endometrial cancer benefit ( Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston, USA )

Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC

Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA

Adagrasib pembrolizumab combo shows promise for KRASG12C-positive NSCLC ( Dr Pasi Janne - Dana-Farber Cancer Institute, Boston, USA )

CheckMate-77T: Perioperative nivolumab benefit for NSCLC

Dr Tina Cascone - MD Anderson Cancer Center, Houston, USA

CheckMate-77T: Perioperative nivolumab benefit for NSCLC ( Dr Tina Cascone - MD Anderson Cancer Center, Houston, USA )

IMS 2023: Multiple myeloma roundup

Prof Philippe Moreau - University Hospital of Nantes, Nantes, Franc

IMS 2023: Multiple myeloma roundup ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, Franc )

More from ecancer